{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:13Z","timestamp":1791902593585,"version":"4.3.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Advancing Clinical Therapeutics Globally"},{"DOI":"10.13039\/100017973","name":"International Maternal Pediatric Adolescent AIDS Clinical Trials Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015003","name":"ACTG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI068634"],"award-info":[{"award-number":["UM1AI068634"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI068636"],"award-info":[{"award-number":["UM1AI068636"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI106701"],"award-info":[{"award-number":["UM1AI106701"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI068616"],"award-info":[{"award-number":["UM1AI068616"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI068632"],"award-info":[{"award-number":["UM1AI068632"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI106716"],"award-info":[{"award-number":["UM1AI106716"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["K24AI165099"],"award-info":[{"award-number":["K24AI165099"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"NICHD","doi-asserted-by":"publisher","award":["HHSN275201800001I"],"award-info":[{"award-number":["HHSN275201800001I"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"NICHD","doi-asserted-by":"publisher","award":["UM1AI069465"],"award-info":[{"award-number":["UM1AI069465"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johns Hopkins University Baltimore-India Clinical Trials Unit","award":["UM1AI154463"],"award-info":[{"award-number":["UM1AI154463"]}]},{"name":"Aurum Institute Clinical Trials Unit"},{"name":"Georgia Tuberculosis Research Advancement Center","award":["P30AI168386"],"award-info":[{"award-number":["P30AI168386"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multidrug-resistant tuberculosis (MDR-TB) remains a global health threat and accounts for a quarter of deaths due to antimicrobial resistance. Individuals infected with MDR-TB are at risk of progressing to TB disease. Treatment of drug-resistant TB infection to prevent progression to disease and avert the associated morbidity and mortality is a global priority. Randomized evidence to inform TB preventive treatment (TPT) guidelines has been lacking. Two recently completed trials provide the first randomized evidence that treatment of household contacts exposed to people with MDR-TB with daily levofloxacin for 6 months is safe and efficacious in preventing TB. Based on these results, the World Health Organization updated its TPT guidelines to make a strong recommendation for use of levofloxacin for 6 months in MDR-TB exposed contacts. Novel, shorter regimens in development will usher in a new era for the treatment of MDR-TB infection if shown to be safe and efficacious.<\/jats:p>","DOI":"10.1093\/cid\/ciaf426","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:36:08Z","timestamp":1754393768000},"page":"1135-1140","source":"Crossref","is-referenced-by-count":4,"title":["Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-3699","authenticated-orcid":false,"given":"Gavin J","family":"Churchyard","sequence":"first","affiliation":[{"name":"Aurum Institute , Head Office, Parktown ,","place":["South Africa"]},{"name":"School of Public Health, University of Witwatersrand , Johannesburg ,","place":["South Africa"]},{"name":"Department of Medicine, Vanderbilt University , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5826-6037","authenticated-orcid":false,"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-2718","authenticated-orcid":false,"given":"Amita","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, School of Medicine, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-0857","authenticated-orcid":false,"given":"N Sarita","family":"Shah","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[{"name":"Harvard TH Chan, School of Public Health, Harvard University , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4776-6092","authenticated-orcid":false,"given":"Soyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Harvard TH Chan, School of Public Health, Harvard University , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg J","family":"Fox","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harrington","sequence":"additional","affiliation":[{"name":"Treatment Action Group , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, School of Medicine, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke C","family":"Hesseling","sequence":"additional","affiliation":[{"name":"Desmond Tutu TB Centre, Stellenbosch University , Stellenbosch ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"2026020907371323300_ciaf426-B1","volume-title":"Global tuberculosis report 2023","author":"WHO","year":"2023"},{"key":"2026020907371323300_ciaf426-B2","author":"World Health Organization"},{"key":"2026020907371323300_ciaf426-B3","volume-title":"Global tuberculosis report 2024","author":"WHO","year":"2024"},{"key":"2026020907371323300_ciaf426-B4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(15)00458-0","article-title":"Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis","volume":"3","author":"Kendall","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026020907371323300_ciaf426-B5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1473-3099(19)30307-X","article-title":"Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling","volume":"19","author":"Knight","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026020907371323300_ciaf426-B6","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/cid\/ciad301","article-title":"1-Year incidence of tuberculosis infection and disease among household contacts of rifampin- and multidrug-resistant tuberculosis","volume":"77","author":"Krishnan","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026020907371323300_ciaf426-B7","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.1016\/j.jctube.2024.100449","article-title":"Multidrug-resistant tuberculosis in children: a practical update on epidemiology, diagnosis, treatment and prevention","volume":"36","author":"Gaensbauer","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026020907371323300_ciaf426-B8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cit643","article-title":"Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis","volume":"58","author":"Shah","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026020907371323300_ciaf426-B9","doi-asserted-by":"crossref","first-page":"2100266","DOI":"10.1183\/13993003.00266-2021","article-title":"The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis","volume":"58","author":"Velen","year":"2021","journal-title":"Eur Respir J"},{"key":"2026020907371323300_ciaf426-B10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/cid\/ciaa613","article-title":"Concordance of drug-resistance profiles between persons with drug-resistant tuberculosis and their household contacts: a systematic review and meta-analysis","volume":"73","author":"Chiang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026020907371323300_ciaf426-B11","first-page":"278","article-title":"The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era","volume":"8","author":"Marais","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026020907371323300_ciaf426-B12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciz235","article-title":"Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease","volume":"70","author":"Gupta","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026020907371323300_ciaf426-B13","doi-asserted-by":"crossref","first-page":"e0283290","DOI":"10.1371\/journal.pone.0283290","article-title":"Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household","volume":"18","author":"Kim","year":"2023","journal-title":"PLoS One"},{"key":"2026020907371323300_ciaf426-B14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/cid\/ciz254","article-title":"Willingness to take multidrug-resistant tuberculosis (MDR-TB) preventive therapy among adult and adolescent household contacts of MDR-TB Index cases: an international multisite cross-sectional study","volume":"70","author":"Suryavanshi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026020907371323300_ciaf426-B15"},{"key":"2026020907371323300_ciaf426-B16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/pathogens11101189","article-title":"Preventive therapy for contacts of drug-resistant tuberculosis","volume":"11","author":"Kherabi","year":"2022","journal-title":"Pathogens"},{"key":"2026020907371323300_ciaf426-B17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026020907371323300_ciaf426-B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmi.2023.09.015","article-title":"Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"30","author":"Zhou","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026020907371323300_ciaf426-B19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1164\/rccm.201501-0069OC","article-title":"Fluoroquinolone therapy for the prevention of multidrug-resistant tuberculosis in contacts. A cost-effectiveness analysis","volume":"192","author":"Fox","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020907371323300_ciaf426-B20"},{"key":"2026020907371323300_ciaf426-B21","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","article-title":"Levofloxacin preventive treatment in children exposed to MDR tuberculosis","volume":"391","author":"Hesseling","year":"2024","journal-title":"N Engl J Med"},{"key":"2026020907371323300_ciaf426-B22","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","article-title":"Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam","volume":"391","author":"Fox","year":"2024","journal-title":"N Engl J Med"},{"key":"2026020907371323300_ciaf426-B23","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400190","article-title":"A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis","volume":"4","author":"Duong","year":"2025","journal-title":"NEJM Evid"},{"key":"2026020907371323300_ciaf426-B24","volume-title":"Module 1: prevention\u2014tuberculosis preventive treatment","author":"WHO consolidated guidelines on tuberculosis","year":"2024","edition":"2nd ed"},{"key":"2026020907371323300_ciaf426-B25","doi-asserted-by":"crossref","first-page":"19719","DOI":"10.1038\/s41598-024-70535-y","article-title":"Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study","volume":"14","author":"Nehru","year":"2024","journal-title":"Sci Rep"},{"key":"2026020907371323300_ciaf426-B26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/0976-500X.136121","article-title":"Delamanid: a new armor in combating drug-resistant tuberculosis","volume":"5","author":"Xavier","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"key":"2026020907371323300_ciaf426-B27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026020907371323300_ciaf426-B28","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1128\/AAC.02658-13","article-title":"Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis","volume":"58","author":"Lanoix","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020907371323300_ciaf426-B29","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"2026020907371323300_ciaf426-B30","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1164\/rccm.201908-1576OC","article-title":"Isoniazid preventive therapy in contacts of multidrug-resistant tuberculosis","volume":"202","author":"Huang","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020907371323300_ciaf426-B31","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1111\/bph.14867","article-title":"Isoniazid and host immune system interactions: a proposal for a novel comprehensive mode of action","volume":"176","author":"Khan","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2026020907371323300_ciaf426-B32","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.7326\/M20-7577","article-title":"Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial","volume":"174","author":"Churchyard","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026020907371323300_ciaf426-B33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2026020907371323300_ciaf426-B34","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.201103-0397OC","article-title":"Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection","volume":"184","author":"Zhang","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 4","key":"2026020907371323300_ciaf426-B35","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.1093\/cid\/ciac672","article-title":"Potential impact of long-acting products on the control of tuberculosis: preclinical advancements and translational tools in preventive treatment","volume":"75","author":"Ammerman","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026020907371323300_ciaf426-B36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1164\/rccm.202012-4541OC","article-title":"Efficacy of long-acting bedaquiline regimens in a mouse model of tuberculosis preventive therapy","volume":"205","author":"Kaushik","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020907371323300_ciaf426-B37","doi-asserted-by":"crossref","first-page":"e00007-19","DOI":"10.1128\/AAC.00007-19","article-title":"Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020907371323300_ciaf426-B38","author":"Hobson"},{"key":"2026020907371323300_ciaf426-B39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5588\/ijtldopen.24.0670","article-title":"Patient and provider preferences for long-acting TB preventive therapy","volume":"2","author":"Vermeulen","year":"2025","journal-title":"IJTLD Open"},{"key":"2026020907371323300_ciaf426-B40","volume-title":"Target product profiles for tuberculosis preventive treatment","author":"WHO","year":"2020"},{"key":"2026020907371323300_ciaf426-B41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12916-022-02378-1","article-title":"Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis","volume":"20","author":"Vesga","year":"2022","journal-title":"BMC Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf426\/63975945\/ciaf426.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/1135\/63975945\/ciaf426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/1135\/63975945\/ciaf426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:37:25Z","timestamp":1770640645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/6\/1135\/8224917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf426","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,15]]},"published":{"date-parts":[[2025,8,7]]}}}